CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $221.12M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 0.92: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
221.12MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.8050xvs all stocks
52-Week Change
139.34%vs all stocks
Market Capitalization
221.12MUSDvs all stocks (USD)
Enterprise Value
154.12MUSDvs all stocks (USD)
Forward P/E
-2.35xvs Biotechnology peers
Price to Book (MRQ)
1.53xvs Biotechnology peers
Enterprise to EBITDA
-2.47xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-19.77%vs Biotechnology peers
Return on Equity (TTM)
-33.69%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-62.49MUSDvs all stocks (USD)
Net Income (TTM)
-57.09MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-49.86MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-28.88MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-66.84MUSDvs all stocks (USD)
Pre-tax Income
-59.00MUSDFY2025 · Dec 31, 2025Net Income
-59.00MUSDFY2025 · Dec 31, 2025EBIT
-66.84MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-60.37MUSDFY2025 · Dec 31, 2025Research & Development
41.11MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
25.73MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
7.87MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-59.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-50.45MUSDFY2025 · Dec 31, 2025Free Cash Flow
-51.73MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
13.39MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-59.00MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
6.46MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.84MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-69.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.69MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.28MUSDFY2025 · Dec 31, 2025Purchase of Investments
-72.49MUSDFY2025 · Dec 31, 2025Sale of Investments
108.99MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
35.22MUSDFY2025 · Dec 31, 2025Shares Outstanding
127.07MSharesUpdated Jul 19, 2026Float Shares
55.81MSharesUpdated Jul 19, 2026Shares Short
829.52KSharesUpdated Jul 19, 2026Short Ratio
0.9700daysvs all stocks
Short % of Shares Outstanding
1.33%vs all stocks
% Held by Insiders
33.21%vs all stocks
% Held by Institutions
40.78%vs all stocks
Total Cash (MRQ)
95.87MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7540USDUpdated Jul 19, 2026Total Debt (MRQ)
28.87MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1999xvs Biotechnology peers
Current Ratio (MRQ)
11.85xvs Biotechnology peers
Book Value per Share (MRQ)
1.14USDUpdated Jul 19, 2026Total Assets
191.11MUSDvs all stocks (USD)
Total Current Assets
105.96MUSDFY2025 · Dec 31, 2025Total Liabilities
34.14MUSDFY2025 · Dec 31, 2025Total Non-current Assets
85.15MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
26.19MUSDFY2025 · Dec 31, 2025Total Current Liabilities
7.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
12.39MUSDFY2025 · Dec 31, 2025Other Short-term Investments
91.02MUSDFY2025 · Dec 31, 2025Accounts Payable
943.00KUSDFY2025 · Dec 31, 2025Short-term Debt
3.83MUSDFY2025 · Dec 31, 2025Other Current Liabilities
183.00KUSDFY2025 · Dec 31, 2025Long-term Debt
26.19MUSDFY2025 · Dec 31, 2025Common Stock (Book)
13.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-332.02MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
156.97MUSDvs all stocks (USD)
52-Week Low
0.6200USDUpdated Jul 19, 202652-Week High
4.31USDUpdated Jul 19, 202652-Week Change
139.34%vs all stocks
Beta
0.8050xvs all stocks
50-Day MA
2.29USDUpdated Jul 19, 2026200-Day MA
2.20USDUpdated Jul 19, 2026Avg 10-Day Volume
955.15KSharesUpdated Jul 19, 2026Avg 30-Day Volume
977.92KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.4600USDUpdated Jul 19, 2026Other Income / Expense
-32.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 11.85Altman Z-Score: 0.92
Financial Health
Altman Z-Score 0.92: distress zoneCritical
Altman Z-Score: 0.92
Low earnings qualitySignificant
Earnings Quality Score: -0.72
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $221.12M, lower than 95% of all stocks globallySignificant
Market cap (USD): 221,117,207Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Intocell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Acimmune SA
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Invivyd Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Proteina Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMaking
Tomocube Inc.
Tier 1ProductionApproval-Gated PipelineSenseMaking
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Neuromeka Co., Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated